Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celgene-CELG -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (307)	5/17/1999 11:56:00 PM
From: Miljenko Zuanic	Read Replies (2) \| Respond to of 804

Peter: I am glad that you posted news, otherwise will be responding to myself. << The study of 71 patients determined the combination of THALOMID® (thalidomide) and carboplatin to be active in recurrent GBM. Of the 45 patients who were evaluated for efficacy, 27% (12) had progressive disease and the rest either had stable disease or tumor regression. The most common side effects reported were constipation and drowsiness. >> First time that someone report numbers of progressive disease as measure for active and beneficial therapy. Like they are afraid to report numbers on disease stabilization and tumor regression. Hope they will be more specific on Crohn's trials result. Miljenko